Bone Marrow GvHD after Allogeneic Hematopoietic Stem Cell Transplantation

Szyska, Martin; Na, Il‐Kang

doi:10.3389/fimmu.2016.00118

Cited by 52 publications

(41 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Bone marrow gives rise to all hematopoietic lineages and is the homing site for memory cells of the adaptive immunity (102). Recently, BM has been established as an additional target of alloreactivity observed during GvHD leading to the depletion of both hematopoietic progenitors and niche-forming cells (103), resulting in disrupted hematopoiesis and delayed immune reconstitution (104).…”

Section: Adaptive Immunitymentioning

confidence: 99%

Immune Reconstitution after Allogeneic Hematopoietic Stem Cell Transplantation

et al. 2016

View full text Add to dashboard Cite

The timely reconstitution and regain of function of a donor-derived immune system is of utmost importance for the recovery and long-term survival of patients after allogeneic hematopoietic stem cell transplantation (HSCT). Of note, new developments such as umbilical cord blood or haploidentical grafts were associated with prolonged immunodeficiency due to delayed immune reconstitution, raising the need for better understanding and enhancing the process of immune reconstitution and finding strategies to further optimize these transplant procedures. Immune reconstitution post-HSCT occurs in several phases, innate immunity being the first to regain function. The slow T cell reconstitution is regarded as primarily responsible for deleterious infections with latent viruses or fungi, occurrence of graft-versus-host disease, and relapse. Here we aim to summarize the major steps of the adaptive immune reconstitution and will discuss the importance of immune balance in patients after HSCT.

show abstract

Section: Adaptive Immunitymentioning

confidence: 99%

Immune Reconstitution after Allogeneic Hematopoietic Stem Cell Transplantation

et al. 2016

View full text Add to dashboard Cite

show abstract

“…But despite immunosuppressant therapy, immune rejection in the form of GVHD is still a major cause of morbidity and mortality, occurring in 30 ~ 40 % of allogeneic HSC transplantations [53]. The presence of allo-reactive donor lymphocytes is the crucial reason for GVHD, which are responsible for the inflammatory injury to multiple organs, most commonly the skin, gastrointestinal tract, and liver [54, 55]. The clinical application of MSCs for GVHD developed more rapidly than for any other type of immune-/inflammation-mediated diseases, likely due in large part to a case report in which a pediatric patient with severe GVHD was infused with haploindentical BMMSCs with dramatic therapeutic effect [14].…”

Section: State Of Msc Clinical Research In Specific Immune-/inflammatmentioning

confidence: 99%

Human mesenchymal stem cells (MSCs) for treatment towards immune- and inflammation-mediated diseases: review of current clinical trials

et al. 2016

View full text Add to dashboard Cite

Human mesenchymal stem cells (MSCs) are multilineage somatic progenitor/stem cells that have been shown to possess immunomodulatory properties in recent years. Initially met with much skepticism, MSC immunomodulation has now been well reproduced across tissue sources and species to be clinically relevant. This has opened up the use of these versatile cells for application as 3rd party/allogeneic use in cell replacement/tissue regeneration, as well as for immune- and inflammation-mediated disease entities. Most surprisingly, use of MSCs for in immune-/inflammation-mediated diseases appears to yield more efficacy than for regenerative medicine, since engraftment of the exogenous cell does not appear necessary. In this review, we focus on this non-traditional clinical use of a tissue-specific stem cell, and highlight important findings and trends in this exciting area of stem cell therapy.

show abstract

“…In patients with life-threatening disease, such as hematologic malignancies and inborn errors of metabolism or the immunodeficiency allogeneic stem cell transplantation is a conceivable curative treatment (2). This was before the identification of major histocompatibility complex (MHC), a key feature to success in allogeneic hematopoietic stem cell transplantation (HSCT).…”

Section: Introductionmentioning

confidence: 99%

Stem cell transplantation during cancer

Zhang

2016

Oncology Letters

View full text Add to dashboard Cite

Hematological malignancies account for approximately 9.5% of new cancers diagnosed annually. Lymphoma is the most frequent of all known categories of hematological malignancies. Worldwide, extensive research has focused on this type of cancer. However, new treatments are investigated in various clinical as well as pre-clinical studies. Hematopoietic stem cell transplantation (HSCT) is a recent and upcoming treatment strategy for patients with hematopoietic malignancies and inborn errors of metabolism or immune deficiencies. Recent studies have revealed that successful clinical outcome of this treatment strategy depends on multiple factors including the protocol applied, disease under treatment, health of the patient, source of the grafts, severity of complications such as graft versus host disease during grafting and associated infections. The scope of this review is to achieve greater understanding of various clinical effects of the disease and related mechanisms. The electronic database Pubmed was searched for pre-clinical as well as clinical controlled trials reporting efficacy of the HSCT against hematological malignancies.

show abstract

Bone Marrow GvHD after Allogeneic Hematopoietic Stem Cell Transplantation

Cited by 52 publications

References 58 publications

Immune Reconstitution after Allogeneic Hematopoietic Stem Cell Transplantation

Immune Reconstitution after Allogeneic Hematopoietic Stem Cell Transplantation

Human mesenchymal stem cells (MSCs) for treatment towards immune- and inflammation-mediated diseases: review of current clinical trials

Stem cell transplantation during cancer

Contact Info

Product

Resources

About